The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.
 
Ali Raza Khaki
Stock and Other Ownership Interests - Pfizer; Procter & Gamble; Walgreens Boots Alliance
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Ang Li
No Relationships to Disclose
 
Michael Edward Devitt
Consulting or Advisory Role - Bayer
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Kyn therapeutics (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kyn therapeutics; RADMETRIX
Research Funding - Kite/Gilead
Patents, Royalties, Other Intellectual Property - My significant other has 5 patents with UCLA. (I)
Travel, Accommodations, Expenses - Lilly
 
Evan Shreck
No Relationships to Disclose
 
Monika Joshi
Consulting or Advisory Role - Sanofi
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
 
Pedro Isaacsson Velho
No Relationships to Disclose
 
Lucia Alonso
Travel, Accommodations, Expenses - MSD; Pfizer; Roche
 
Ariel Ann Nelson
No Relationships to Disclose
 
Sandy Liu
Consulting or Advisory Role - Exelixis; Sanofi
Speakers' Bureau - Exelixis; Genentech; Merck
Travel, Accommodations, Expenses - Exelixis
 
Marcus W. Moses
No Relationships to Disclose
 
Pedro C. Barata
Consulting or Advisory Role - Bayer
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; Dendreon; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Seagen; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)
 
Veena Shankaran
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Gary H. Lyman
Stock and Other Ownership Interests - Generex Biotechnology
Consulting or Advisory Role - Agendia; Amgen; Celldex (I); G1 Therapeutics; Genomic Health; Halozyme; Helsinn Therapeutics; Janssen (I); Mylan; Partners Healthcare; Pfizer; Samsung Bioepis; Spectrum Pharmaceuticals
Research Funding - Hexal
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)